Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU

Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) in February 2023.

Melbourne (Australia) and Indianapolis, IN (U.S.) – 22 December 2022. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to inform shareholders that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (^{89}Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.

ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary endpoints as well as specific grading criteria related to lesion size and detection.

In addition, six presentations on Telix's carbonic anhydrase IX (CAIX)- and prostate specific membrane antigen (PSMA)-targeting theranostic candidates will be featured in the program. Presentations will report on advancements in positron emission tomography (PET) imaging of prostate cancer with ^{68}Ga PSMA-11; the potential utility of TLX250-CDx in tumour types beyond ccRCC; and the STARLITE Phase II studies, which are assessing the efficacy of TLX250 (^{177}Lu-DOTA-girentuximab) targeted radiation in combination with immunotherapy for ccRCC.

Dr Colin Hayward, Telix Chief Medical Officer, said, "Telix's vision is to drive innovation in urologic oncology across the patient continuum, harnessing the power of targeted radiation from imaging, to surgery and therapy. We are therefore excited to be so well represented at ASCO-GU, the leading specialised event for GU cancer care worldwide. A highlight will be the first presentation of finalised, detailed clinical data from the Phase III ZIRCON study of TLX250-CDx, which reported highly positive topline data in November.[1] The congress program also includes updates on Telix-sponsored and investigator-initiated diagnostic and therapeutic studies and research collaborations across prostate and kidney cancer, and other tumour types. We look forward to seeing you at our booth."

ASCO GU presentation materials will published to the ASX, and an investor conference call and webcast will be held following presentation of results with joining details to be announced closer to the event.

ZIRCON presentation details at ASCO GU are as follows:

Session: Oral Abstract Session C: Renal and Rare Tumors
Title: *Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON)*
Date and Time: 18-Feb-2023, 2:00 PM-3:30 PM
Presenter: Dr. Brian Shuch (UCLA)
Abstract ID: LBA602

[1] ASX disclosure 7 November 2022.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

TLX250-CDx (^{89}Zr-DFO-girentuximab) has not received a marketing authorisation in any jurisdiction. Telix's lead product, gallium-68 (^{68}Ga) gozetotide (also known as ^{68}Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[2] and by the Australian Therapeutic Goods Administration (TGA),[3] and by Health Canada.[4]

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

[2] ASX disclosure 20 December 2021.
[3] ASX disclosure 2 November 2021.
[4] ASX disclosure 14 October 2022.